Celldex Therapeutics, Inc. (NASDAQ:CLDX) Focus o

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Focus on Wall Street Ratings
by Franklin Staff — April 28, 2016

Wall Street brokerage firms have marked Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares with a Buy/Sell rating of 2. This is based on the 8 sell-side research analysts taken into consideration by Zacks Research. Using a sliding integer based scale, the lower the number the better as a 1 indicates a Strong Buy and a 5 a Strong Sell.

In addition to the average broker rating, we can look at where the analysts view the stock moving in the near term. In the sell-side reports given to institutions, the research firms often offer a projected target price on the stock. The time frame and criteria can differ depending on the firm, so to get a general feel for where they see the stock heading, we view the consensus number. Based on the 8 analysts providing stock targets, the highest is currently at $24 and the lowest is $4. The mean, or consensus number is $8.75.

Looking at the earnings health of the stock, analysts are expecting that the company will report earnings of $-0.34 per share for the current quarterly period on or around 2016-05-04. Last quarter the firm posted earnings of $-0.33 for the quarter. This was $0.01 away from the analyst consensus, yielding a surprise factor of 2.94%. Large surprise factors can lead to significant stock price movement in the days and months following an earnings report. The Street will be watching to see if the firm will meet or

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!

Alway's searching for winners'